Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent.

BACKGROUND Over 2000 protein kinases regulate cellular functions. Screening for inhibitors of some of these kinases has already yielded some potent and selective compounds with promising potential for the treatment of human diseases. RESULTS The marine sponge constituent hymenialdisine is a potent inhibitor of cyclin-dependent kinases, glycogen synthase kinase-3beta and casein kinase 1. Hymenialdisine competes with ATP for binding to these kinases. A CDK2-hymenialdisine complex crystal structure shows that three hydrogen bonds link hymenialdisine to the Glu81 and Leu83 residues of CDK2, as observed with other inhibitors. Hymenialdisine inhibits CDK5/p35 in vivo as demonstrated by the lack of phosphorylation/down-regulation of Pak1 kinase in E18 rat cortical neurons, and also inhibits GSK-3 in vivo as shown by the inhibition of MAP-1B phosphorylation. Hymenialdisine also blocks the in vivo phosphorylation of the microtubule-binding protein tau at sites that are hyperphosphorylated by GSK-3 and CDK5/p35 in Alzheimer's disease (cross-reacting with Alzheimer's-specific AT100 antibodies). CONCLUSIONS The natural product hymenialdisine is a new kinase inhibitor with promising potential applications for treating neurodegenerative disorders.

[1]  L. Tsai,et al.  The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity , 1998, Nature.

[2]  J. Kimura,et al.  Cyclin-dependent Kinase 5 and Mitogen-activated Protein Kinase in Glial Cytoplasmic Inclusions in Multiple System Atrophy , 1998, Journal of neuropathology and experimental neurology.

[3]  J. Leet,et al.  Antineoplastic agents. 168. Isolation and structure of axinohydantoin , 1990 .

[4]  E. Sausville,et al.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.

[5]  S. Kim,et al.  High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. , 1996, Journal of medicinal chemistry.

[6]  G. N. Ramachandran,et al.  Stereochemistry of polypeptide chain configurations. , 1963, Journal of molecular biology.

[7]  P. Cohen,et al.  The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[8]  Y. Kyōgoku,et al.  Marine Natural Products. XII. On the Chemical Constituents of the Okinawan Marine Sponge Hymeniacidon aldis , 1983 .

[9]  D. H. Williams,et al.  Isomers and Tautomers of Hymenialdisine and Debromohymenialdisine , 1996 .

[10]  L. Mazzarella,et al.  4-(2-Amino-4-oxo-2-imidazolin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one methanol solvate: a new bromo compound from the sponge Acanthella Aurantiaca , 1982 .

[11]  L. Meijer,et al.  Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. , 1999, Journal of medicinal chemistry.

[12]  William Hyde Wollaston,et al.  I. The Croonian Lecture , 1810, Philosophical Transactions of the Royal Society of London.

[13]  L. Meijer,et al.  Chemical inhibitors of cyclin-dependent kinases , 1997 .

[14]  D. Faulkner,et al.  Stevensine, a novel alkaloid of an unidentified marine sponge , 1985 .

[15]  J. Woodgett,et al.  Baculovirus-mediated expression and characterisation of rat glycogen synthase kinase-3 beta, the mammalian homologue of the Drosophila melanogaster zeste-white 3sgg homeotic gene product. , 1992, European journal of biochemistry.

[16]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[17]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[18]  I. Grundke‐Iqbal,et al.  Phosphorylation of τ Protein by Casein Kinase‐1 Converts It to an Abnormal Alzheimer‐Like State , 1995, Journal of neurochemistry.

[19]  A. Mizuno,et al.  Synthesis of Pyrroloazepines. Facile Synthesis of 2‐Substituted Pyrrole Derivatives by the Phosgene Method. , 1997 .

[20]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.

[21]  J. Blow,et al.  Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.

[22]  B. Anderton,et al.  Alzheimer's disease: Clues from flies and worms , 1999, Current Biology.

[23]  L. Meijer,et al.  Intra-M Phase-promoting Factor Phosphorylation of Cyclin B at the Prophase/Metaphase Transition* , 1999, The Journal of Biological Chemistry.

[24]  M. Hatten,et al.  Neuronal regulation of astroglial morphology and proliferation in vitro , 1985, The Journal of cell biology.

[25]  T. Hunter,et al.  The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  C. Haass,et al.  Proteolytic fragments of the Alzheimer's disease associated presenilins-1 and -2 are phosphorylated in vivo by distinct cellular mechanisms. , 1998, Biochemistry.

[27]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.

[28]  Jean Claude Braekman,et al.  Chemotaxonomy of Agelas (Porifera: Demospongiae) , 1992 .

[29]  M. Mercken,et al.  Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Fattaey,et al.  CDK inhibition and cancer therapy. , 1999, Current opinion in genetics & development.

[31]  S. Kaech,et al.  Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations , 1999, Biological Psychiatry.

[32]  L. Tsai,et al.  p35, the Neuronal-specific Activator of Cyclin-dependent Kinase 5 (Cdk5) Is Degraded by the Ubiquitin-Proteasome Pathway* , 1998, The Journal of Biological Chemistry.

[33]  P. Salinas,et al.  Inhibition of GSK-3 β leading to the loss of phosphorylated MAP-1 B is an early event in axonal remodelling induced by WNT-7 a or lithium , 1998 .

[34]  L Meijer,et al.  Multiple modes of ligand recognition: Crystal structures of cyclin‐dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine , 1995, Proteins.

[35]  K. Yakushijin,et al.  Synthesis of C(11)N(5) Marine Sponge Alkaloids: (+/-)-Hymenin, Stevensine, Hymenialdisine, and Debromohymenialdisine. , 1997, The Journal of organic chemistry.

[36]  Hans Clevers,et al.  Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis , 1998, Nature.

[37]  D. Melton,et al.  A molecular mechanism for the effect of lithium on development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Ávila,et al.  Lithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neurons , 1997, FEBS letters.

[39]  R. I. Fryer,et al.  Reinvestigation into the structure of oroidin, a bromopyrrole derivative from marine sponge , 1973 .

[40]  J. Clardy,et al.  Sceptrin, an antimicrobial agent from the sponge Agelas sceptrum , 1981 .

[41]  S H Kim,et al.  Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Pettit.  Progress in the discovery of biosynthetic anticancer drugs. , 1996, Journal of natural products.

[43]  S. Kim,et al.  Purification and crystallization of human cyclin-dependent kinase 2. , 1993, Journal of molecular biology.

[44]  J. Buyer,et al.  Characterization of a yellow compound isolated from the marine sponge Phakellia flabellata , 1980 .

[45]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[46]  Sung-Hou Kim,et al.  Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.

[47]  L. Mazzarella,et al.  Isolation and X-ray crystal structure of a novel bromo-compound from two marine sponges , 1982 .

[48]  S. Leroy,et al.  Agelastatin a, a new skeleton cytotoxic alkaloid of the oroidin family. Isolation from the axinellid sponge Agelas dendromorpha of the coral sea , 1993 .

[49]  William Hyde Woollaston.  Croonian Lecture. , 1810, The Medical and physical journal.

[50]  A. Takashima,et al.  Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid β peptide (25–35) enhances phosphorylation of tau in hippocampal neurons , 1998, Neuroscience Research.

[51]  J. H. Wang,et al.  Association of Neurofilament Proteins with Neuronal Cdk5 Activator* , 1998, The Journal of Biological Chemistry.

[52]  L. Marshall,et al.  Inhibition of NFκB-Mediated Interleukin-1β-Stimulated Prostaglandin E2 Formation by the Marine Natural Product Hymenialdisine , 1997 .

[53]  Virginia M. Y. Lee,et al.  Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3* , 1997, The Journal of Biological Chemistry.

[54]  D. Selkoe,et al.  The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease , 1998 .

[55]  T. Lindel,et al.  Chemical defense of the Caribbean sponge Agelas clathrodes (Schmidt) , 1997 .

[56]  L. Johnson,et al.  Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 , 1997, Nature Structural Biology.

[57]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[58]  R. A. Crowther,et al.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease , 1989, Neuron.

[59]  E. Krebs,et al.  Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[60]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[61]  E. Fattorusso,et al.  Dispacamides, anti-histamine alkaloids from Caribbean Agelas sponges , 1996 .

[62]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[63]  Doris Marko,et al.  Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases , 1999, Nature Cell Biology.

[64]  M. Pinter,et al.  Alterations in Cyclin-Dependent Protein Kinase 5 (CDK5) Protein Levels, Activity and Immunocytochemistry in Canine Motor Neuron Disease , 1998, Journal of neuropathology and experimental neurology.

[65]  R. Carnuccio,et al.  A novel bromopyrrole alkaloid from the sponge Agelas longissima with antiserotonergic activity , 1995 .

[66]  J. Brion,et al.  Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. , 1995, The American journal of pathology.

[67]  L Meijer,et al.  Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. , 1999, Cancer research.

[68]  M. Boyd,et al.  Antineoplastic agents. 362. Isolation and X-ray crystal structure of dibromophakellstatin from the Indian ocean sponge Phakellia mauritiana. , 1997, Journal of natural products.

[69]  P. Salinas,et al.  WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons. , 1997, Developmental biology.

[70]  S H Kim,et al.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.

[71]  L. Meijer,et al.  ATP-site directed inhibitors of cyclin-dependent kinases. , 1999, Current medicinal chemistry.

[72]  J. Avila,et al.  Implication of cyclin‐dependent kinases and glycogen synthase kinase 3 in the phosphorylation of microtubule‐associated protein 1B in developing neuronal cells , 1998, Journal of neuroscience research.

[73]  K. Imahori,et al.  Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. , 1997, Journal of biochemistry.

[74]  P. Jeffrey,et al.  Structural basis of cyclin-dependent kinase activation by phosphorylation , 1996, Nature Structural Biology.

[75]  P. Fraser,et al.  The Presenilin 1 Protein Is a Component of a High Molecular Weight Intracellular Complex That Contains β-Catenin* , 1998, The Journal of Biological Chemistry.

[76]  E. Mandelkow,et al.  Proteolysis by presenilins and the renaissance of tau. , 1999, Trends in cell biology.

[77]  J. Breton,et al.  The natural product hymenialdisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-kappaB. , 1997, The Journal of pharmacology and experimental therapeutics.

[78]  E. Mandelkow,et al.  Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding , 1993, Neuron.

[79]  E. Mandelkow,et al.  Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. , 1998, European journal of biochemistry.

[80]  E. Mandelkow,et al.  Overexpression of Tau Protein Inhibits Kinesin-dependent Trafficking of Vesicles, Mitochondria, and Endoplasmic Reticulum: Implications for Alzheimer's Disease , 1998, The Journal of cell biology.

[81]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[82]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[83]  R. Goold,et al.  Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. , 1998, Journal of cell science.

[84]  E. Sausville,et al.  Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. , 1994, Biochemical and biophysical research communications.

[85]  H. Annoura,et al.  Total syntheses of hymenialdisine and debromohymenialdisine: Stereospecific construction of the 2-amino-4-oxo-2-imidazolin-5(Z)-disubstituted y ylidene ring system , 1995 .

[86]  A. Mizuno,et al.  SYNTHESIS OF PYRROLOAZEPINES. FACILE SYNTHESIS OF 2-SUBSTITUTED PYRROLE DERIVATIVES BY THE PHOSGENE METHOD , 1997 .